Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

  • High Dose Chemotherapy Significantly Prolongs Survival for Patients with Acute Myeloid Leukemia
    (Posted: 11/17/2008) - Preliminary results from a large, randomized clinical trial for patients ages 16 to 60 with previously untreated acute myeloid leukemia, a cancer of the blood and bone marrow, show that patients who received a high dose of a commercially available chemotherapy drug, daunorubicin, during initial therapy lived longer than patients who received a standard dose of the same drug.
  • Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
    (Posted: 09/17/2008) - Computerized tomographic colonography, also known as virtual colonoscopy, is comparable to standard colonoscopy, which uses a long, flexible tube with a camera to view the lining of the colon, in its ability to accurately detect cancer and precancerous polyps and could serve as an initial screening exam for colorectal cancer, according to the results of the American College of Radiology Imaging Network National CT Colonography Trial.
  • Zoledronic Acid Prevents Bone Loss During Estrogen-Suppression Treatment of Breast Cancer
    (Posted: 01/09/2007, Updated: 09/16/2008) - Zoledronic acid can prevent treatment-induced bone loss in premenopausal women undergoing total estrogen suppression after surgery for hormone-responsive breast cancer, according to an article published online Jan. 3, 2007, in the Journal of Clinical Oncology.
  • Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
    (Posted: 06/26/2007, Updated: 09/16/2008) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux®) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy alone, according to findings presented at the 2007 ASCO meeting in Chicago.
  • Bevacizumab (Avastin®) Benefits Some Patients With Advanced Kidney Cancer
    (Posted: 06/20/2007, Updated: 01/22/2008) - Addition of the targeted drug bevacizumab (Avastin®) to interferon alfa staved off disease progression for significantly longer than a placebo in patients with advanced kidney cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
< Previous  21 22 23 24 25 26 27 28 29 30 31 32 33  Next >